Beijing VJTBio and Shenzhen Rehgen Bio held a strategic cooperation signing ceremony for the development of mRNA vaccines against major animal diseases and zoonotic diseases. Both parties fully discussed and exchanged views on project cooperation advancement planning and product globalization. Attendees at the signing ceremony included Dr. Hu Yong, General Manager, and Dr. Hu Zhaoyu, Deputy General Manager of Rehgen Bio, as well as Dr. Luo Haoshu, Chairman, Mr. Xiong Jiansheng, General Manager, Ms. Han Guo, Vice President, and leaders of the R&D department of VJTBio.

This strategic cooperation represents a strong alliance between a leading animal innovative drug company and a biotechnology company with globally leading mRNA technology. It is believed that the comprehensive and in-depth cooperation between VJTBio and Rehgen Bio will surely help the country better address the challenges and issues of major animal diseases and zoonotic diseases, providing important support for the high-quality development of China's high-tech modern agriculture and the health of the people.

The Nobel Prize in Physiology or Medicine awarded in October 2023 honored two outstanding scientists who made significant contributions to mRNA vaccine development. Since the outbreak of the COVID-19 pandemic in 2019, this disease has claimed millions of lives worldwide and caused trillions of dollars in economic losses. Innovative companies represented by Moderna and BioNTech have successfully developed mRNA vaccines against COVID-19, which have unique advantages in simultaneously stimulating humoral and cellular immunity. Therefore, they have achieved remarkable success in preventing the COVID-19 pandemic and brought health benefits to people worldwide. Humans and animals coexist on Earth, and animal diseases and zoonotic diseases have been rampant globally for nearly 30 years, causing significant losses and threats to agriculture and economic development. From mad cow disease, foot-and-mouth disease, avian influenza, and PRRS to African swine fever, which entered China in 2018, these major diseases have caused significant losses and threats to China's animal husbandry industry.

As a global animal innovative drug company, VJTBio has collaborated with renowned experts and professors in animal infectious disease for many years. Together, they have researched the pathogenesis of major animal diseases and zoonotic diseases, establishing a high-throughput screening method for complex viral antigen epitope combinations. They have also constructed a core technology platform for the development of new vaccines and therapeutic drugs targeting highly variable complex viruses, with mRNA vaccines being one of the main technological pathways. VJTBio has currently developed two patented mRNA vaccines for economic and companion animals.

Rehgen Bio possesses a complete mRNA product research and development platform, and has accumulated rich experiences in mRNA vaccine and drug development, with multiple pipelines entered the clinical stage. To support VJTBio in developing mRNA vaccines targeting complex viruses, Rehgen Bio will provide integrated mRNA product development solutions through its wholly-owned subsidiary, ENO Biotechnology , including AI algorithm-based mRNA sequence design and synthesis, proprietary Cap structure analogs and delivery systems, CMC formulation process development, and GMP production services.

During the signing ceremony, Dr. Luo Haoshu, Chairman of VJTBio, and Dr. Hu Yong, General Manager of Rehgen Bio , expressed their high expectations and strategic determination for this cooperation. In the future, VJTBio will continues to strengthen its collaboration with top biotechnology companies , and committes to promoting high-quality industry development through innovation, specialization, and sustainability."